Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Break that resistance past 4.50 go go.
Yes it's a new article. Basically saying to buy up now or wait until the resistance is passed at around 4.50
Good price movement today, there seems to be some resistance while waiting for the next catalyst.
Shorts and longs have an opportunity here.
Morbidity is in reference to a human being or animal, not an organization. Indifference is neither caring or not caring usually associated with individuals. Again how is a publicly traded company ( Intellipharmaceutics) even if appropriately or metaphorically described as diseased related to isolation of neither caring or not caring.
I actually love Philosophy. A good thing about Philosophy as it applies to the financial markets is that it enhances your critical thinking faculties, and enables you to identify bull crap and falsehoods in the market and elsewhere.
I don't know, I believe dilution is going to be a significant factor in the income first quarter financials.
The revenue generated will not be enough to compare to the dilution that's currently taking place due to the selling of stock from the ATM. my optimism is pessimistic.
Dilution is taking the stock to new lows today. It's forthcoming so be careful. Just a warning for all you share holders here.
Excuse me, I meant water under the bridge.
The Lawsuit Tamarin Lindenberg has is about money. It has nothing to do with Arrayit's business and what they are trying to accomplish. They are moved into the new headquarters, engaging financiers, progressing to CLIA and ISO certification, and OvaDx development and FDA application submission.
Anything else with Tamarin Lindenberg is water under the river.
Good luck IPCI retailers. Please read and try to understand the earnings report and make good decisions based on due diligence. Understand the companies goals and make intelligent comparisons with other companies in the sector.
See the value and opportunity here. Have a good trading day everyone.
That's right they did receive FDA approval and they are receiving revenue from a commercial product, and there are other products in the pipeline and the capital raised was favorable to the share structure. Thank you for elaborating.
Great earnings release. Revenue revenue revenue.
Last comment for me:
You are assuming that I don't think you do.
I am indifferent to that fact. Good luck and happy v day.
200 shares to bring down to .3451. Lol. The usual games with aryc. Going to enjoy valentines day. Good luck everyone.
Good luck everyone today. Happy valentines day. I'm going to go enjoy it now.
It's metaphor/ or is that allegory? Anyway, my point is that for those that understand Intellipharmaceutics company goals, we are still at the growth process of this growth company.
The first product is the pipelines was approved and is generating revenue for the company which was a goal.
So now, the other products currently under FDA review have the ability to add to the amount of revenue to be produced.
More products, more revenue. Over time the revenue will just increase even if there are some failures along the way.
In my opinion IPCI absolutely will be generating revenue of over 100 million dollars yearly without Rexista oxycodone,
If they can produce positive studies for Rexista, and file with the FDA, forget it, it's staying above 10 dollars like doogdilinger has predicted.
There's a bit of buying going on this week.
Has anyone researched the timeframe for CLIA and ISO certification. I will soon and post to the board.
We are still here and it's been a great ride so far.
The best thing about it is that, it's still the beginning of the ride. We aren't even halfway through yet.
There is one fda approved product the IS generating revenue, and there are many other potential revenue producers in the pipeline, that haven't been factored into the price.
That makes no sense to what is currently happening. As the facts are in the filings, press releases, and charts, but most of what is said here in opinion.
I have to agree with Pedro2004 here. I think a share buy back is not in the near future. The share structure is already very good.
Though in the future, there may come a time, after revenue has increased and the share price has appreciated significantly; the company will do a split.
Good
I have also mentioned this.
There has been accumulation going on in the past week we some large buys in anticipation of some possible news announcements leading to the fiscal year 2013 report, as well as q1 coming to a close and q2 about to start.
Revenue!
Very nice.
That's good. Networking is good for the company.
Nice, I'll keep my eye on them if they decide to go public.
We have been here for a long time. Seen it above 1 dollar and below 10 cents. It a great ride. This a coming together very nicely for ArrayIt this year. It's quiet but I like it that way for now. It's a good accumulation point. I was in the ride from below 15 cents all the way to 80 cents. It was great. Good luck too you.
It will be interesting to see how much of the $3.1M is booked in the first quarter financial report.
Of course. That is obvious.
If it beats estimate it's usually a positive indicator. Considering they received FDA approval in November at the very end of the fiscal year.
Very good volume here today. I woke up so late and looked at the tickers and saw IPCI is the green as expected this week.
Congratulations to those of you who are holding this and are very happy with your accounts right now.
As the market makes a downturn because of the FED tapering on dumping money in the economy, be smart with you profits and buy assets. This year may be a rough ride for the markets... again...
I think IPCI is in a very good position to whether the storm because of the product pipeline, and revenues coming in.
They have proven that the technology is capable of garnering FDA approvals and that they can successfully partner, and now the revenue is another validating driver for shareholder value.
2014 holds a lot of northward share price drivers for the stock. There will still be opportunity for short selling, but you have to really predict it accurately as it may become increasingly risky. Good luck!
The Kyrgyz government may be too corrupt to legitimately do business there. I will keep Stans on the RADAR though.
Will keep that in mind. Thank you. Best if wishes to you both on the road to health.
Same here if they decide to cover Arrayit.
Bartlman, I also would like to express my sympathy to your situation by saying one thing. Which in my opinion expresses all. "Om"
I understand the whole picture you are trying to frame on this message board fnamelname42. The fact of the matter is that Howell resigned and there is absolutely no deal or anything with Tamarin Lindenberg.
All of the what if's about her potential involvement in OvaDx or Diagnostics is meaningless. She is a non factor, so is Howell.
Arrayit Corporation management has made it clear what the CURRENT goals are, and are on path to accomplishing them in steps.
New money
New facility
New certifications
New studies
New filings
Etc...
Very good news for Arrayit and shareholders. Let's go!
@arrayit: Arrayit pipeline CLIA/ISO labs equipped with new air conditioning. 75-ton crane places 7,800 lb unit on ARYC roof top http://t.co/eRi3h3Tjxo
Near early-mid October last year Arrayit did make a dip under 35 cents then bounced back up to over 80cents. This is a good buying opportunity.
I'm absolutely confident that Arrayit will. It just gets to me sometimes, how they Allow the share price to take such a beating sometimes.
Remember the run we had last year. This is possible again.
Oh, by the way, create a darn pipeline page already. Clearly show through the website that you are serious about CLIA, ISO, and diagnostics. There should be a one stop page for clearly understanding the companies goals and developments on these fronts.